• Earlier this month, Ultragenyx Pharmaceutical reported that the US FDA accepted its resubmitted Biologics License Application for UX111, an investigational AAV9 gene therapy for Sanfilippo syndrome Type A, and set a PDUFA action date of 19 September.
• If UX111 is ultimately approved, it could become the first available treatment for this rare, fatal pediatric neurodegenerative disorder, marking a potentially important expansion of Ultragenyx’s rare-disease gene therapy portfolio.
• We’ll now examine how FDA acceptance of the UX111 resubmission, and the upcoming September decision, could reshape Ultragenyx’s investment narrative.

Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

Ultragenyx Pharmaceutical Investment Narrative Recap

To own Ultragenyx, you typically need to believe that its rare disease focus and late stage gene therapy pipeline can eventually overcome current losses and heavy cash burn. The FDA’s acceptance of the UX111 resubmission meaningfully reinforces the near term regulatory catalyst story, but it also sharpens the key risk that setbacks at UX111 or DTX401 could further delay Ultragenyx’s path toward its stated 2027 profitability goal.

Among recent announcements, the FDA’s Priority Review of DTX401 for glycogen storage disease type Ia, with an August 23 PDUFA date, is especially relevant. Together with UX111’s September 19 PDUFA date, Ultragenyx now faces two closely spaced US regulatory decisions that could significantly influence future cash generation and funding needs, particularly given 2025 net losses of US$575,000,000 and ongoing restructuring aimed at lowering expenses.

Yet while UX111’s progress may be encouraging, investors should be aware of the ongoing risk that high quarterly R&D spend and net losses could still...

Ultragenyx Pharmaceutical's narrative projects $1.3 billion revenue and $69.1 million earnings by 2029.

Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.45 fair value, a 109% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming only about 12.8 percent annual revenue growth and no profitability within three years, highlighting how differently you might weigh UX111’s regulatory risks versus concentrated pipeline dependence.

Explore 2 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth over 10x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.